GOSSAMER BIO INC

Gossamer Bio’s insider option exercise signals a potential $0.16 upside if FDA clears seralutinib, showing unified exec confidence and a chance for investors.

Gossamer Bio insider buying signals bullish confidence amid a promising immunology pipeline and regulatory fast‑track, but legal and liquidity risks remain.

Gossamer Bio insider option buys signal confidence in its late‑stage immunology‑oncology pipeline and convertible‑note strategy, hinting at future value.